ALGS

Aligos Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 6/10
  • Value↓ 0/10
Aligos Therapeutics sales and earnings growth
ALGS Growth
Good
  • Revenue Y/Y↑ 42.17%
  • EPS Y/Y↑ 14.16%
  • FCF Y/Y↓ -7.82%
Aligos Therapeutics gross and profit margin trends
ALGS Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1919.70%
  • ROIC 5Y↓ -283.87%
Aligos Therapeutics net debt vs free cash flow
ALGS Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -24.3

Aligos Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks